ONE-WAYDated event · through FY2025-H1

Acquisition of an ADC drug discovery platform through the acquisition of Araris Biotech

An individual M&A transaction to strengthen the drug discovery and development platform for antibody-drug conjugates (ADCs) by making Araris Biotech AG a wholly owned subsidiary and acquiring the AraLinQ™ ADC linker platform and 3 preclinical products.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2024 →Last written FY2025-H1

Directionhelps1 helps · 0 hurts · 0 flat